Epidemiology of amyotrophic lateral sclerosis in the Krasnoyarsk region
https://doi.org/10.17650/2222-8721-2023-13-4-20-29
Abstract
Background. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes paralysis of muscles due to degeneration of motor neurons. According to available data, the incidence of ALS in different regions of the world is from 0.6 to 3.8 per 100,000 population per year. Data obtained during the study of the epidemiology of ALS at the regional level can be used in planning medical resources, in particular, calculating the necessary respiratory equipment and funds for nutritional support.
Aim. Clinical and epidemiological analysis of ALS cases registered in the Krasnoyarsk region for the period 2018–2022.
Materials and methods. A clinical and epidemiological analysis of ALS cases registered in the Krasnoyarsk region from 2018 to 2022 was conducted. To do this, we used data from the specialized office of neuromuscular pathology of the Regional Clinical Hospital in Krasnoyarsk and the Krasnoyarsk Regional Medical Information and Analytical Center. Diagnosis verification was carried out in accordance with the generally accepted El Escorial and Gold Coast criteria. The functional state and degree of neurological deficit were assessed using the ALS-FRS-R scale.
Results. Over the period from 2018 to 2022, 78 cases of ALS were registered. The incidence rate was 0.54 cases per 100,000 population per year. In 2022, the prevalence rate was 1.16 cases per 100 thousand population. The time from symptom onset to diagnosis of the disease ranged from 4 to 57 months, with the average time to diagnosis being 17 months. Most patients were diagnosed with ALS when their ALS-FRS-R score decreased by 7–11 points. The division of patients into groups of rapid, moderate, and slow diagnostic correlates with life expectancy. Patients who are diagnosed quickly have a higher rate of disease progression, which results in a low life expectancy.
Conclusion. The creation of specialized centers will improve the diagnosis and management of patients with ALS and plan the costs of palliative care. The increase in the incidence and detection of ALS emphasizes the need to develop new approaches to the treatment and rehabilitation of patients with ALS.
About the Authors
E. A. Ermilov
Regional Clinical Hospital
Russian Federation
Russian Federation
3А Partizana Zheleznyaka St., Krasnoyarsk 660022
N. V. Isaeva
Regional Clinical Hospital; Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1 Partizana Zheleznyaka St., Krasnoyarsk 660022
References
1. Kacem I., Sghaier I., Bougatef S. et al. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort. Amyotroph Lateral Scler Frontotemporal Degener 2020;21(1-2): 131–9. DOI: 10.1080/21678421.2019.1704012
2. Trojsi F., D'Alvano G., Bonavita S., Tedeschi G. Genetics and sex in the pathogenesis of amyotrophic lateral sclerosis (ALS): Is there a link? Int J Mol Sci 2020;21(10):3647. DOI: 10.3390/ijms21103647
3. Garmonov M.S. On the issue of diagnosis and treatment of amyotrophic lateral sclerosis. Vselennaya nozga = Brain Universe 2019;1(2):9–13. (In Russ.)
4. Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr Opin Neurol 2019;32(5):771.
5. Longinetti E., Regodon Wallin A., Samuelsson K. et al. The Swedish motor neuron disease quality registry. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:528–37.
6. Palese F., Sartori A., Verriello L. et al. Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002–2014: A retrospective population-based study. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(1–2):90–9. DOI: 10.1080/21678421.2018.1511732
7. Benjaminsen E., Alstadhaug K., Gulsvik M. et al. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000–2015: Prevalence, incidence, and clinical features. Amyotroph Lateral Scler Frontotemporal Degener 2018;19(7–8):522–7.
8. Jun K.Y., Park I., Oh K.-W. et al. Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry 2019;90(4):395–403. DOI: 10.1136/jnnp-2018-318974
9. Turgut N., Varol SaraÇoglu G., Kat S. et al. An epidemiologic investigation of amyotrophic lateral sclerosis in Thrace, Turkey, 2006–2010. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(1–2):100–6. DOI: 10.1080/21678421.2018.1525403
10. Zhou S., Zhou Y., Qian S. et al. Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015. Multicenter Study Brain Behav 2018;8(11):e01131. DOI: 10.1002/brb3.1131
11. Leighton D.J., Newton J., Stephenson L. et al. Changing epidemiology of motor neurone disease in Scotland. J Neurol 2019;266(4):817–25. DOI: 10.1007/s00415-019-09190-7
12. Rose L., McKim D., Leasa D. et al. Trends in incidence, prevalence, and mortality of neuromuscular disease in Ontario, Canada: A population-based retrospective cohort study (2003–2014). PLoS One 2019;14(3):e0210574. DOI: 10.1371/journal.pone.0210574
13. Fedotova T.V., Platova Yu.A. Features of the course of amyotrophic lateral sclerosis in patients of the neurological department of the Ulyanovsk Regional Clinical Hospital. National projects – a priority for the development of regional healthcare: Materials of the 54th interregional scientific and practical medical conference, Ulyanovsk, May 16–17, 2019. Ulyanovsk: IP Petrova L.V., 2019. Pp. 296–298. (In Russ.)
14. Brylev L., Ataulina A., Fominykh V. et al. The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia). Amyotroph Lateral Scler Frontotemporal Degener 2020;21(5–6):410–5. DOI: 10.1080/21678421.2020.1752252
15. Davydova T.K., Nikolaeva T.Ya. Amyotrophic lateral sclerosis in Yakutia. Sibirskiy meditsinskiy zhurnal = Siberian Medical Journal 2007;S2:23–5. Available at: https://cyberleninka.ru/article/n/bokovoy-amiotroficheskiy-skleroz-v-yakutii. (In Russ.)
16. Samoshkina O.I. Clinical and epidemiological features of amyotrophic lateral sclerosis in Saint Petersburg and the Leningrad region. Abstract. dis. ... cand. med. sciences. Saint Petersburg, 2007. 25 p. (In Russ.)
17. Pervushina E.V., Bakhtiyarova K.Z. Clinical characteristics of amyotrophic lateral sclerosis in the Republic of Bashkortostan. Prakticheskaya meditsina = Practical Medicine 2015;5(90):108–10. (In Russ.)
18. Criteria and revised El Escorial Criteria in the diagnosis of amyotrophic lateral sclerosis (ALS) at first visit in a Tunisian cohort. Neurol Res Int 2021:2021:8841281. DOI: 10.1155/2021/8841281
19. Brooks B.R., Miller R.G., Swash M. et al. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5): 293–9. DOI: 10.1080/146608200300079536
20. Hannaford A., Pavey N., van den Bos M. et al. Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Ann Neurol 2021;89(5):979–86. DOI: 10.1002/ana.26045
21. Palese F., Sartori A., Logroscino G., Edith Pisa F. Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotroph Lateral Scler Frontotemporal Degener 2019;20(3–4): 176–85. DOI: 10.1080/21678421.2018.1550517
22. Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol 2020;27(10):1918–29. DOI: 10.1111/ene.14393
Review
For citations:
Ermilov E.A., Isaeva N.V. Epidemiology of amyotrophic lateral sclerosis in the Krasnoyarsk region. Neuromuscular Diseases. 2023;13(4):20‑29. (In Russ.) https://doi.org/10.17650/2222-8721-2023-13-4-20-29
Views:
697
Email this article 